The role of toxicity-related regimen changes in the development of antiretroviral resistance

AIDS Research and Human Retroviruses

Volumn 27, Issue 9, 2011, Pages 957-963

  Nevin, Christa R ^a   Ye, Jiatao ^b   Aban, Inmaculada ^b   Mugavero, Michael J ^a   Jackson, David ^a   Lin, Hui Yi ^b   Allison, Jeroan ^c   Raper, James L ^a   Saag, Michael S ^a   Willig, James H ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; RACE; RISK FACTOR; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 80052068406     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2010.0291     Document Type: Article

References (40)

1. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, and Montaner JS: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294. (Pubitemid 27192475)
2. Maggiolo F, Ripamonti D, Airoldi M, Callegaro A, Arici C, Ravasio V, Bombana E, Goglio A, and Suter F: Resistance costs and future drug options of antiretroviral therapies: Analysis of the role of NRTIs, NNRTIs, and PIs in a large clinical cohort. HIV Clin Trials 2007;8:9-18. (Pubitemid 46542905)
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860. (Pubitemid 28135961)
4. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, Wood E, Dong WW, Montaner JS, and Harrigan PR: Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006;3:e356.
5. Mauro Z, Federica F, Patrizia L, Francesca CS, Valerio T, Paola TM, Patrizia M, Pasquale N, Federico PC, and Andrea A: Continuous evidence of fast HIV disease progression related to class-wide resistance to antiretroviral drugs: A 6 year follow-up analysis of a large observational database. AIDS 2007;21:1824-1826. (Pubitemid 47237575)
6. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, Gori C, Narciso P, Perno CF, and An-tinori A: Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005;19:1081-1089. (Pubitemid 40961149)
7. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, and Carrieri MP: Factors associated with non-adherence to long-term highly active antiretroviral therapy: A 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 2009;64:599-606.
8. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, and Batte-gay M: Treatment modification in human immunodeficiency virus-infected individuals starting combination anti-retroviral therapy between 2005 and 2008. Arch Intern Med 2010;170:57-65.
9. Davidson I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B, Nelson M and Stebbing J. The frequency and reasons for antiretroviral switching with specific anti-retroviral associations: The SWITCH study. Antiviral Res 2010;86:227-229
10. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, An-tinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, and Moroni M: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Anti-retroviral-Naive Patients. AIDS 2000;14:499-507.
11. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J 3rd, Hernandez F, Tomatis C, Saag MS, and Gotuzzo E: Durability of initial antiretroviral therapy in a resource constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010;53:215-221.
12. Braitstein P, Ayuo P, Mwangi A, Wools-Kaloustian K, Mu-sick B, Siika A, and Kimaiyo S: Sustainability of first-line antiretroviral regimens: Findings from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr 2010;53:254-259.
13. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, Gunthard HF, and Bucher HC: Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2010;54:197-203.
14. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:1-19.
15. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, Saag MS, and Mugavero MJ: Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951-1960.
16. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kur-itzkes DR, Pillay D, Schapiro JM, and Richman DD: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
17. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, and Verdon R: Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004;38:1311-1316. (Pubitemid 38608576)
18. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, and Montaner JS: Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347. (Pubitemid 40139758)
19. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Ver-nazza PL, Rickenbach M, Ledergerber B, and Gunthard HF: Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis 2008;46:1299-1309. (Pubitemid 351589918)
20. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, Carpenter S, Giddy J, Ross D, Holst H, Losina E, Walker BD, and Kuritzkes DR: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597. (Pubitemid 351706742)
21. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, and Gunthard HF: Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: A comparison of different regimen types. Arch Intern Med 2007;167:1782-1790. (Pubitemid 47403067)
22. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, and Eron JJ Jr: Triple-class antiretroviral drug resistance: Risk and predictors among HIV-1-infected patients. AIDS 2007;21:825-834. (Pubitemid 46573154)
23. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, and Yeni P: Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS 2002;16:2447-2454. (Pubitemid 35471693)
24. Lactic Acisosis International Study Group: Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007;21:2455-2464.
25. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, and Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201. (Pubitemid 38917996)
26. Margot NA, Enejosa J, Cheng AK, Miller MD, and McColl DJ: Development of HIV-1 Drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, te-nofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in Study GS-01-934. J Acquir Immune Defic Syndr 2009;52:209-221.
27. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, and Solomon S: Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr 2009;55:155-159.
28. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, Balakrishnan P, Yepthomi T, Poon-gulali S, Flanigan TP, Solomon S, and Mayer KH: Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008;22:337-344. (Pubitemid 351562965)
29. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, and Stringer JS: Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 2010;54:63-70.
30. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, and D'Aquila RT: Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997;126:929-938. (Pubitemid 27255795)
31. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, and Hamilton JD: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to anti-retroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997;126:939-945. (Pubitemid 27255796)
32. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, and Hamilton JD: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996;334:426-431. (Pubitemid 26055842)
33. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Gunthard HF, Gilks C, and Pillay D: Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: A systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-417.
34. Levine RS, Briggs NC, Kilbourne BS, King WD, Fry-Johnson Y, Baltrus PT, Husaini BA, and Rust GS: Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007;97:1884-1892. (Pubitemid 351182302)
35. Moore RD, Stanton D, Gopalan R, and Chaisson RE: Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-768. (Pubitemid 24080224)
36. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, Hellinger J, Keiser P, Rubin HR, Crane L, Hel-linger FJ, and Mathews WC: Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103. (Pubitemid 40094126)
37. Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, Wray NP, Cole SR, Schumacher JE, Davies S, and Saag MS: Racial disparities in HIV virologic failure: Do missed visits matter? J Acquir Immune Defic Syndr 2009;50:100-108.
38. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, Johnson EN, Ordonez CE, Wort-mann GW, and Marconi VC: Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009;52:574-580.
39. Uy J, Armon C, Buchacz K, Wood K, and Brooks JT: Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009;51:450-453.
40. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, and Shaefer M: Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007;8:1-8. (Pubitemid 46542904)